TSLA
Tesla
-- 355.840 NVDA
NVIDIA
-- 138.850 INTC
Intel
-- 23.600 NBIS
NEBIUS
-- 44.490 PLTR
Palantir
-- 119.160 
NEWS
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
Lipella Pharmaceuticals (Nasdaq: LIPO) announced the issuance of U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform. The patent, titled 'Delivery of Agents Using Metastable Liposomes,' extends market exclusivity for the company's lead clinical assets, LP-10and LP-310, currently in Phase 2 trials. LP-10 is a liposomal formulation of tacrolimus for hemorrhagic cystitis, while LP-310 is an oral rinse for oral lichen planus. The company holds additional patents in the United States, Australia, and Canada, providing exclusivity until 2035.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
8155
Followers
50
Following
93K
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call